SUMMARY Background
In chronic hepatitis C, the European Association for the Study of the Liver and the Asociacion Latinoamericana para el Estudio del Higado recommend performing transient elastography plus a blood test to diagnose significant fibrosis; test concordance confirms the diagnosis.
Aim
To validate this rule and improve it by combining a blood test, FibroMeter (virus second generation, Echosens, Paris, France) and transient elastography (constitutive tests) into a single combined test, as suggested by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
Methods
A total of 1199 patients were included in an exploratory set (HCV, n = 679) or in two validation sets (HCV AE HIV, HBV, n = 520). Accuracy was mainly evaluated by correct diagnosis rate for severe fibrosis (pathological Metavir F ≥ 3, primary outcome) by classical test scores or a fibrosis classification, reflecting Metavir staging, as a function of test concordance.
Results
Score accuracy: there were no significant differences between the blood test (75.7%), elastography (79.1%) and the combined test (79.4%) (P = 0.066); the score accuracy of each test was significantly (P < 0.001) decreased in discordant vs. concordant tests. Classification accuracy: combined test accuracy (91.7%) was significantly (P < 0.001) increased vs. the blood test (84.1%) and elastography (88.2%); accuracy of each constitutive test was significantly (P < 0.001) decreased in discordant vs. concordant tests but not with combined test: 89.0 vs. 92.7% (P = 0.118). Multivariate analysis for accuracy showed an interaction between concordance and fibrosis level: in the 1% of patients with full classification discordance and severe fibrosis, non-invasive tests were unreliable. The advantage of combined test classification was confirmed in the validation sets.
INTRODUCTION
The non-invasive diagnosis of liver pathological features, especially liver fibrosis, has gained wide acceptance. Recently, the European Association for the Study of the Liver -Asociacion Latinoamericana para el Estudio del Higado (EASL-ALEH) proposed recommendations for the non-invasive evaluation of liver disease severity. 1 For chronic hepatitis C (CHC), it advised performing vibration-controlled transient elastography (VCTE) and a blood test, and accepting the diagnosis of significant fibrosis when the two tests return concordant results. When the tests are discordant, a liver biopsy should be considered. In addition, the authors of the EASL-ALEH guidelines stated that the advantage of test agreement had been demonstrated for a single diagnostic targetsignificant fibrosis-but not for cirrhosis.
More recently, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) recommendations 2 in CHC stated that 'the most efficient approach to fibrosis assessment is to combine direct biomarkers and vibration-controlled transient liver elastography'. 3 The combination to which the quote refers is a statistical combination of a blood test and VCTE. It provides a detailed specific fibrosis classification (but no score) that eliminates the grey zone and thus requires no liver biopsy, 3 in contrast to sequential combinations. 4 We have recently improved this combination, 5 providing a gain in accuracy driven by two elements: first, the statistical combination of blood markers (instead of blood test) and VCTE into a unique score (ranging from 0 to 1); and second, the translation of this score into a Metavir fibrosis classification with six fibrosis classes according to a previously developed 6 and validated 7 statistical method. Most studies on blood-elastography combinations have not demonstrated or validated (i.e. in validation set) a statistical gain for combination against the most accurate single constitutive test. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The few that have were either limited to a single diagnostic target like significant fibrosis, [21] [22] [23] severe fibrosis 24 or cirrhosis, 25 or used a nonclassical fibrosis classification. 3, 5, 23 But in these latter papers, the impact of constitutive test discordance was not evaluated. For the present study, our primary objective was to validate the EASL-ALEH reliability rule based on test concordance for the diagnosis of severe fibrosis in CHC with liver biopsy as reference. Our secondary objective was to evaluate whether our combined unique fibrosis test might improve the EASL-ALEH rule as suggested by the AASLD-IDSA statement.
PATIENTS AND METHODS

Overall design
Aetiology. Chronic hepatitis C was the aetiology used for the EASL-ALEH guidelines and the construction of most tests, and was therefore retained for the exploratory population and first validation population of the present study. The CHC exploratory population used here was large and well documented, offering in particular detailed morphometric data.
Metrics. Liver fibrosis is measured on a liver specimen, taken by biopsy, according to two main metrics: the usual semi-quantitative staging performed by pathologist (e.g. from stage F0 to F4 in the Metavir system) and the quantitative morphometric measurement performed by software, which provides an area (or surface, expressed in %) of fibrosis. Considering non-invasive measurement by blood tests, liver fibrosis is usually measured according to a score expressing the probability (i.e. from 0 to 1 or 100%) of a diagnostic target (usually significant fibrosis) via a statistical transformation. This score is proportional to, and thus can be translated into fibrosis stages reflecting pathological staging (Figure 1 ). This last metric is called a classification 7 to distinguish it from the original pathological staging. Thus, for pathological and noninvasive evaluation, there are two metrics, a semi-quantitative staging/classification and a quantitative scoring. It should be noted that the former is the most frequently used expression for pathology while the latter is the most frequently used for blood tests.
Outcomes. The primary outcome was severe fibrosis defined as pathological Metavir F ≥ 3 since this is an important clinical target for complication screening and anti-viral treatment. Indeed, this diagnostic target was used in the EASL-ALEH guidelines as an indication for therapy in CHC [see decision tree algorithm including test concordance (Figure 1 ) in the EASL-ALEH guidelines 1 ]. This outcome also corresponds to the new outcome recently defined at the Baveno VI conference as compensated advanced chronic liver disease. 26 Secondary outcomes, that is, significant fibrosis (F ≥ 2) and cirrhosis (F = 4), are reported in the Supporting information.
Judgement criteria. The main judgement criterion was the diagnostic accuracy of non-invasive tests expressed as the percentage of correctly classified patients, as this is the only way to compare diagnostic accuracies between the two fibrosis metrics (score and classification).
Objectives. The study protocol conformed to the ethical guidelines of the current Declaration of Helsinki and received Institutional Review Board approval. All patients gave informed written consent.
Methods
Liver biopsy. Liver biopsies were performed using Menghini's technique with a 1.4-1.6 mm diameter needle. Biopsy specimens were fixed in a formalin-alcohol-acetic solution and embedded in paraffin; 5 lm thick sections were then cut and stained with haematoxylin-eosin-saffron. Liver fibrosis was evaluated according to Metavir fibrosis (F) stages by two senior experts with a consensus reading in case of discordance in Angers and in the Fibrostar centres, and by a senior expert in other patients in Bordeaux and Grenoble. These liver specimen findings served as a reference for the liver fibrosis evaluation by non-invasive tests. The areas of whole, sinusoidal and porto-septal fibrosis and of steatosis were centrally measured by automated morphometry as recently described 28 by a single engineer under the control of an experienced liver pathologist. is a blood test that was constructed for Metavir fibrosis staging in CHC in another derivation population. 6 Liver stiffness : Liver stiffness was assessed using VCTE with the M probe (Fibroscan, Echosens, Paris, France) by experienced operators (>100 examinations before the study), blinded for patient data. Examination conditions were those previously described. 29 analysed on an intention-to-diagnose basis, i.e. all raw data were included without exclusion, especially for VCTE irrespective of reliability criteria. 33 Statistical indices were calculated from individual data.
Accuracy:
The diagnostic accuracy of each fibrosis test was expressed with two descriptors. The first descriptor, limited to scorings, was the area under the receiver operating characteristic curve (AUROC), i.e. the classical index for binary diagnostic targets. The second descriptor was the percentage of correctly classified patients. We evaluated this correct classification rate in the two metrics. In the scoring metric, the classical binary diagnosis by score, for example, F < 3 vs. F ≥ 3 stages, was obtained by a single cut-off; this cut-off was determined by the maximum Youden index maximising sensitivity and specificity. In the fibrosis classification metric (or just classification hereafter), the cut-off was determined by the threshold value between the fibrosis classes 2 and 3 ( Figure 1 ). Respectively for the scoring and classification, the score cut-offs for severe fibrosis were 0.695 and 0.717 for FibroMeter V2G , 9.15 and 10.9 kPa for VCTE, and 0.676 and 0.772 for FibroMeter
VCTE2G
. The exploratory set was the derivation population for classification of VCTE and FibroMeter VCTE2G as previously published. 5, 30 To minimise differences in cut-off determination, cut-offs of scoring metrics were also calculated in the exploratory set so that they were determined in a comparable manner for both metrics. The same cut-off values were then applied to the validation sets. Test discordance was simply defined as different results for severe fibrosis between the two constitutive tests (FibroMeter V2G and VCTE) regarding the two metrics.
For example, discordance by scoring means that the first test value lies below the score cut-off for severe fibrosis (i.e. located in a single class corresponding to Metavir F < 3) and the second test value above that cut-off (i.e. located in a single category F ≥ 3). For fibrosis classification, discordance means that the first constitutive test value lies below the lowest cut-off of class 3 (i.e. range including three classes: 0, 1/2, 2) while the second constitutive test value lies above that cut-off (i.e. range including three classes: 3, 3/4, 4) ( Figure 1 ). All other class combinations were defined as test concordance.
Reliability: We evaluated whether certain patient characteristics had a significant impact on accuracy level, i.e. the reliability of a test result.
Sample size calculation: The size of the population was that necessary to detect a significant difference between Software: The main statistical analyses were performed under the control of two professional statisticians using SPSS version 18.0 (IBM, Armonk, NY, USA) and SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Table 1 summarises the main characteristics of the exploratory population. The rate of test discordance for severe fibrosis was not significantly different between scoring (28.4%) and classification (26.8%, P = 0.254 by paired McNemar test). Patients with discordant tests (for severe fibrosis according to classification) were typically older males with more fibrosis and activity but with similar BMI compared to patients with concordant tests.
RESULTS
Population characteristics
Accuracy
Accuracy performance. The scoring AUROC for severe fibrosis of the combined test was significantly higher than the scoring AUROCs of its two constitutive tests ( Table 2 ) as expected. More importantly, the scoring AUROCs (and the corresponding rate of patients correctly classified for severe fibrosis, Table 3 ) of the three tests were significantly lower in patients with discordant constitutive tests than in patients with concordant constitutive tests (P < 0.001). Similarly, the rate of patients correctly classified for severe fibrosis by fibrosis classification (Table 3) was also significantly lower (P < 0.001) in patients with discordant constitutive tests than in patients with concordant constitutive tests in the two constitutive tests, but, importantly, this was not the case for the combined test (89% in discordant cases vs. 93% in concordant cases, P = 0.118). Finally, the rates of patients correctly classified for severe fibrosis were significantly higher (P < 0.001) in fibrosis classification than in fibrosis scoring for the three diagnostic tests. The comparison of test accuracy as a function of the concordance status and fibrosis metrics is summarised in Figure 2 .
Accuracy predictors. Multivariate analysis by logistic regression included all clinical data (e.g. age), pathological descriptors and non-invasive biomarkers (e.g. ALT and IQR/median of VCTE). The independent predictors of accuracy of FibroMeter VCTE2G were test concordance (P = 0.001), FibroMeter VCTE2G score (P < 0.001), VCTE median (P < 0.001) and FibroMeter V2G score (P = 0.001) with a significant interaction between test concordance and FibroMeter V2G or VCTE. This means that the fibrosis level interacted with concordance for accuracy prediction. Thus, we found that the accuracy of FibroMeter VCTE2G was significantly decreased in the 3.2% of patients with strict (full) discordance between constitutive tests by the classification metric (Table 4) . Thereafter, we observed in this subgroup that accuracy was significantly decreased only in patients with severe fibrosis by FibroMeter VCTE2G classification ( 92.5% in the other patients of the whole population (P < 0.001).
Validation
In the validation populations, the scoring AUROC for severe fibrosis displayed roughly the same results as in the exploratory population: a significantly higher accuracy for the combined test compared to its two constitutive tests and for all tests in concordant cases compared to discordant cases (except for VCTE in the first validation population with the smallest size) (Tables S1 and  S2 ). Finally, FibroMeter VCTE2G showed significantly higher accuracy in classification compared to scoring. The classification accuracy of FibroMeter VCTE2G was significantly higher than those of its two constitutive tests in the largest population and not significantly different between concordant and discordant cases in both populations (Tables S3 and S4 ).
Clinical handling of discordances
Two main options have to be deliberated. On the one hand, if we consider at first only a classical binary diagnosis by scoring, the concordance of the constitutive test scores validates a correct diagnosis of severe fibrosis; in discordance of the constitutive tests, the combined test classification is to be calculated (Figure 3a) . On the other hand, when opting for the more precise diagnosis by classification, the strict concordance of the constitutive test classifications validates a correct diagnosis; in discordance of the constitutive tests, the calculation of the combined test classification is to be considered (Figure 3b) . This latter setting has to be detailed into two cases ( (Figure 3b) . These previous observations can be summarised simply: in any metric, if the constitutive tests agree, accept the diagnosis; if they do not, opt for the combined test classification (Figure 3c ).
DISCUSSION Originalities
In the present study, we validated the EASL-ALEH rule stating that in the setting of severe or significant (details in Supporting information) fibrosis determination in CHC using a classical score, a fibrosis diagnosis can be accepted when a blood test and VCTE agree. 1 Furthermore, we improved that rule using a unique combination of a blood test (FibroMeter V2G ) and VCTE, called FibroMeter VCTE2G , the result of which was expressed in fibrosis classification. This improvement was built upon two factors. The first was the combination of the constitutive biomarkers into a single score, which provided accuracy significantly higher than either of the constitutive tests alone. The second was the expression of the test score in fibrosis classification including six fibrosis classes. Indeed, with this classification, accuracy was not significantly different between patients with discordant and those with concordant constitutive tests. Here, we also demonstrated that the combined test significantly increases diagnostic accuracy for cirrhosis compared to its constitutive tests (details in Supporting information). This has not been observed with other combined tests according to the EASL-ALEH recommendations 1 : 'In patients with viral hepatitis C, when TE and serum biomarkers results are in accordance, the diagnostic accuracy is increased for detecting significant fibrosis but not for cirrhosis'. Finally, the present results also validate the recent guidelines from the AASLD-IDSA, wherein test combination is suggested in CHC. 2 
Main results
Advantage of a combined test. The superiority of blood test and VCTE combination has been suggested in many studies. It should be noted that the interest of test combination has been circulating among authors for some time, but a demonstration of a statistical advantage in terms of a significant gain in accuracy had remained out Table 3 ). (b) Rules for precise diagnosis by classification metric with accuracies (%) (details in Table 4 ). Strict concordance means similar fibrosis classes, partial concordance means F overlap between fibrosis classes (e.g. classes 2 (F2 AE 1) and 1/2 (F1/2)) and strict discordance means different fibrosis classes without F overlap. (c) Summarisation into a unique rule. Accuracy: <80% in red implying an alternative, 80-87% in orange suggesting an alternative, >87% in green meaning reliable diagnosis.
of reach 10, 15, 20 or not evaluated as a function of test concordance. Reliability. The results presented here add reliability to the interest of the combined test, as this latter remained sufficiently reliable in most patients where its constitutive tests were discordant. Unreliable results were determined thanks to discordance; this unreliable group could not be diagnosed in a previous study where test concordance was not considered. 5 Regarding cases of strict discordance and severe fibrosis, where the combined test was unreliable (accuracy: 44%), maximum requirement of liver biopsies should affect only 1% of patients, compared to 28% with the EASL-ALEH agreement rule in the present study. The classical or new reliability criteria of VCTE 33 had no impact on test discordance or on the present diagnostic algorithms (Figure 3 ).
Limits
Fibrosis classification. The classifications used here have been validated in several papers 5, 6, 30 and independent populations. 7, 37 However, the main question regarding the present study is the apparent relative imprecision of fibrosis classification, for example, the information of fibrosis class 2 (Metavir F2 AE 1). In fact, this classification imprecision reflects Metavir staging imprecision. Indeed, considering an objective pathological descriptor independent of the fibrosis classification metric, like the area of porto-septal fibrosis by morphometry, FibroMeter VCTE2G classification was globally as accurate as Metavir F ( Figure S2 ). Considering objective clinical outcomes, the classification metric of the non-invasive test was more discriminant than Metavir F ( Figure S3 ). 38 Together, these data indicate that the test classifications, although relatively imprecise compared to Metavir staging, are in fact accurate when references are objective outcomes. Finally, for all these reasons, factual classification of non-invasive fibrosis tests can be considered per se as an accurate fibrosis staging metric with its own classes ( Figure 1) . Finally, classification adds precision compared to binary diagnosis by scoring, i.e. 6 vs. 2 fibrosis classes respectively.
Other limits. Generalisability: other diagnostic test combinations, for example, Fibrotest with VCTE, were not evaluated as their formulas or cut-offs were not available. 15, 20, 25 However, other authors should find the same advantages for the combined tests provided they use a factual fibrosis classification instead of score. Indeed, purely descriptive classifications 34, 35 or classifications based on the combination of score cut-offs for different binary diagnostic targets have not been validated. 7 Centralised consensus reading was not available in a minority of liver biopsies. As error in this reference is systematic, it should have no impact on the difference we observed between the non-invasive fibrosis tests. The accuracy of FibroMeter VCTE2G (and VCTE) included an optimism bias in the exploratory population. However, the superiority of FibroMeter VCTE2G for accuracy was validated in independent populations. 24, 27 The improvement conferred by FibroMeter VCTE2G classification, especially in discordant patients, was validated in the present results in a first HCV population then in a second population with HBV or HCV-HIV co-infection (Supporting information), considered a more difficult setting for validation of non-invasive tests for liver fibrosis. The results in the second validation population were more homogeneous than those in the first, probably attributable to the latter's small sample size. In addition, there was a greater probability of selection bias in the more recent first validation population, which was influenced by a liver biopsy indication often based on disagreement between non-invasive tests as recently recommended. 1 VCTE in the present study was performed using only the M probe. We recently suggested that the X probe had no significant impact on the accuracy of VCTE classification or its comparison with FibroMeter V2G classification in patients with NAFLD, an even more difficult population for VCTE accuracy. 37 
Clinical practice
In clinical practice, both agreement and combination rules can be used ( Figure 3 ): in any fibrosis metric, if constitutive tests agree, the diagnosis can be accepted; if they do not, the physician should opt for the combined test classification. It may however be simpler to use the combined test classification in all circumstances since the combined test has no additional cost compared to its constitutive tests. Using the rate of reimbursement of direct costs in France, we calculated that the present noninvasive strategy based on the combined test classification and including a 1% biopsy rescue rate would be around 15 times less expensive than the reference strategy using liver biopsy in every patient, and around four times less expensive than the EASL-ALEH concordance rule including a 28% biopsy rescue rate (details not shown). We note that the combined test classification should be interpreted with caution in the rare cases of strict classification discordance (between the constitutive tests) and severe fibrosis by FibroMeter VCTE2G classification. In summary, test combination offers performance while classification adds precision and concordance adds reliability evaluation. Finally, the main advantage of the proposed combined test classification, compared to the EASL-ALEH concordance rule, is to reduce rate of the biopsy rescue from 28% to 1% of patients. Another advantage it has is to offer more precise staging. This non-invasive strategy is applicable to patients with compensated chronic viral hepatitis to rule severe fibrosis in or out before anti-viral treatment since complication screening will differ. This strategy should be evaluated in NAFLD since the combined test is more accurate. 24, 27 However, its applicability to ALD is less probable. 27 
CONCLUSION
In the present study, we validated the EASL-ALEH concordance rule, determining that diagnostic accuracy is significantly increased when the results of a blood test and those of VCTE agree. However, discordance between these tests, necessitating liver biopsy, is observed in a clinically significant proportion of patients with CHC. This can be avoided using a combination of elastography and blood markers as a single test where the result is expressed in a fibrosis classification. The AASLD-IDSA recommendation to combine fibrosis tests is thus also validated. The fibrosis classification metric has clear advantages: it increases diagnostic accuracy, especially with the combined test, which becomes significantly more accurate than its two constitutive tests in every circumstance, and solves most of discordances between the constitutive tests. Finally, a combined test associating elastography and blood markers, and used with its fibrosis classification, could become the non-invasive reference in CHC, especially for the clinically important diagnosis of severe fibrosis, after independent validation of the present results. Other aetiologies should also be evaluated for test concordance since test combination has shown increased accuracy, especially in NAFLD.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Data S1. Additional results for primary and secondary outcomes.
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